Related Experiment Video
Updated: Jan 27, 2026

Generation of Human Chimeric Antigen Receptor Regulatory T Cells
Published on: January 3, 2025
Chimeric Antigen Receptors for T-Cell Malignancies
Lauren D Scherer1,2, Malcolm K Brenner1,2,3, Maksim Mamonkin1,2,3,4
1Texas Children's Hospital, Houston, TX, United States.
Abstract:
Development of chimeric antigen receptor (CAR)-modified T cells for the treatment of T-lineage leukemia and lymphoma has encountered several unique challenges. The most widely expressed tumor antigen targets for malignant T cells are often also expressed on non-malignant T cells. Transducing T cells with CARs targeted to these shared antigens can therefore promote over-activation or fratricide of CAR T cells, reducing their therapeutic potency. If fratricide is resolved, clinical CAR T cell activity may eliminate normal T-cell subsets and cause temporary immunosuppression. In this review, we summarize the preclinical development of CAR-based therapies for T-cell malignancies and discuss strategies to minimize toxicities associated with on-target fratricide and off-tumor activity.
Insights
Chimeric antigen receptor (CAR) T-cell therapy for T-cell cancers faces challenges. Strategies are needed to prevent CAR T-cells from attacking healthy T-cells, improving treatment safety and effectiveness.
Area of Science:
- Immunology
- Oncology
- Cell Therapy
Background:
- Chimeric antigen receptor (CAR)-modified T cells show promise for treating T-lineage leukemia and lymphoma.
- A key challenge involves targeting tumor antigens that are also present on healthy T cells.
Purpose of the Study:
- To review the preclinical development of CAR T-cell therapies for T-cell malignancies.
- To discuss strategies for mitigating toxicities related to on-target fratricide and off-tumor activity.
Main Methods:
- Review of preclinical studies on CAR T-cell therapy for T-cell malignancies.
- Analysis of strategies to address CAR T-cell-related toxicities.
Main Results:
- Targeting shared antigens can lead to CAR T-cell over-activation or fratricide, reducing efficacy.
- Elimination of normal T-cell subsets by CAR T cells can cause temporary immunosuppression.
Conclusions:
- Minimizing toxicities from on-target fratricide and off-tumor activity is crucial for successful CAR T-cell therapy in T-cell malignancies.
- Further research into targeted strategies is essential for enhancing the safety and effectiveness of these advanced therapies.
More Related Videos
08:04In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
Published on: February 27, 2019
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
Related Concept Videos
Diversity of Antigen Receptors
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
Antigen Presenting Cells
T cells require the help of antigen-presenting cells (APCs), which process foreign antigens into smaller fragments that can be recognized by T cells. These APCs are highly specialized cells that efficiently internalize antigens...
Types of Receptors: Cell Surface Receptors
Internal Receptors
Receptor-mediated Endocytosis
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...